Infectious Diseases in Obstetrics and Gynecology / 2018 / Article / Tab 5

Research Article

Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis

Table 5

Univariate sensitivity analysis of universal rapid HIV screening relative to standard of care I.

VariableDetected rangeEstimated incremental cost ($)Estimated incremental QALYIncremental cost-effectiveness ratio ($/QALY)

QALY per prevention of 1 case of MTCT5~2539,827.831.32~6.6030,185.10~6,037.02
Estimated lifetime medical cost of PAH$250k~$550k57,811.19~(−21,356.02)5.0111,530.13~(−4,259.34)
HIV prevalence0.5%~10%40,396.22~36,539.305.09~4.607,943.45~7,943.45
HIV annual cumulative incidence0.01%~0.15%113,233.84~(−20,316.76)0.58~8.65196,399.01~(−2,348.85)
Cost of rapid test$11.90~$16.3215,661.65~50,341.695.013,123.63~10,040.38
Cost of neonatal prophylaxis$185~$21039,827.83~40,063.205.017,943.45~7,990.39

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.